Clinical Trial

First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the optimal dose (Recommended Phase 2 Dose, RP2D), preliminary safety, and efficacy of gecacitinib (also known as jaktinib) in combination with glucocorticoids as first-line therapy for patients with grade II-IV acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Trial Details
NCT Number NCT07285889
Lead Sponsor First Affiliated Hospital of Zhejiang University
Conditions Acute Graft Versus Host Disease
Enrollment 35 participants
Start Date 2025-12-03
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-16